[ad_1]
Health-care corporations rose because the obesity-drug speculative growth gathered momentum.
Shares of Danish obesity-drug maker Novo Nordisk surged after the corporate mentioned Amycretin, appeared much more efficient than its widespread Wegovy drug in trials. The features pushed the corporate’s market capitalization above $560 billion, placing Novo Nordisk on track to surpass Tesla’s market worth for the primary time since 2020.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
March 07, 2024 17:43 ET (22:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
[adinserter block=”4″]
[ad_2]
Source link